Literature DB >> 8583347

Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids.

K Setoh1, M Murakami, N Araki, T Fujita, A Yamamoto, S Muranishi.   

Abstract

The in-vitro permeability of chemically modified tetragastrin with fatty acids through the rat skin was studied. The permeability of these compounds through intact skin and stripped skin of rat was determined with a Franz-type diffusion cell. The permeation of tetragastrin across the intact skin was improved by chemical modification with acetic acid and butyric acid. However, tetragastrin and caproyl-tetragastrin did not permeate across the intact skin up to the end of experiment. The permeation of tetragastrin across the stripped skin was improved by chemical modification, the skin flux of these acyl derivatives being in the order:acetyl > butyroyl > caproyl. The stability of tetragastrin in skin homogenate was also significantly improved by chemical modification with fatty acids. These results suggest that chemical modifications of tetragastrin with fatty acids increases its lipophilicity, which makes it permeable across the stratum corneum. Moreover, the chemical modification reduced the degradation of tetragastrin in the viable skin, resulting an increase in permeation of tetragastrin across the skin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583347     DOI: 10.1111/j.2042-7158.1995.tb05745.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Enhanced transdermal peptide delivery and stability by lipid conjugation: epidermal permeation, stereoselectivity and mechanistic insights.

Authors:  Sarika Namjoshi; Istvan Toth; Joanne T Blanchfield; Nicholas Trotter; Ricardo L Mancera; Heather A E Benson
Journal:  Pharm Res       Date:  2014-05-21       Impact factor: 4.200

2.  Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

Authors:  T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

3.  Position of lipidation influences anticancer activity of Smac analogs.

Authors:  Ewa D Micewicz; Christine Nguyen; Alina Micewicz; Alan J Waring; William H McBride; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2019-04-26       Impact factor: 2.823

4.  Lipid-conjugated Smac analogues.

Authors:  Ewa D Micewicz; Josephine A Ratikan; Alan J Waring; Julian P Whitelegge; William H McBride; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

5.  Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors.

Authors:  T Fujita; I Kawahara; Y Quan; K Hattori; K Takenaka; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

6.  A two-step strategy to enhance activity of low potency peptides.

Authors:  Jamie R Doyle; Benjamin N Harwood; Subrahmanian Tarakkad Krishnaji; Vijay M Krishnamurthy; Wei-En Lin; Jean-Philippe Fortin; Krishna Kumar; Alan S Kopin
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

7.  Investigation of the N-Terminus Amino Function of Arg10-Teixobactin.

Authors:  Shimaa A H Abdel Monaim; Sikabwe Noki; Estelle J Ramchuran; Ayman El-Faham; Fernando Albericio; Beatriz G de la Torre
Journal:  Molecules       Date:  2017-09-28       Impact factor: 4.411

Review 8.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

9.  Acyl lipidation of a peptide: effects on activity and epidermal permeability in vitro.

Authors:  Daniel Rocco; James Ross; Paul E Murray; Rima Caccetta
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.